Busulfan - Article Myleran
|Systematic (IUPAC) name|
|Pregnancy cat.|| |
|Legal status|| |
Busulfan is a chemotherapy drug that is an alkylating agent (slows the growth of cancer cells). It is marketed in the US by GlaxoSmithKline under the brand name Myleran, and has been in clinical use since 1959. Currently, its main uses are in bone marrow transplantation, especially in Chronic myelogenous leukemia (CML), where it is used as a conditioning drug. Toxicity may include pulmonary fibrosis and hyperpigmentation.
Busulfan also induces thrombocytopenia, a condition of lowered blood platelet count and activity. The drug was recently used in a study (published April 2006, Science) to examine the role of platelet-transported serotonin in liver regeneration.